These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17634871)

  • 1. [HIV infection 2007].
    Potthoff A; Brockmeyer N;
    Med Klin (Munich); 2007 Jul; 102(7):531-9. PubMed ID: 17634871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Salvage therapy in HIV infection].
    Salzberger B
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():52, 54-5, 57. PubMed ID: 15373050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.
    Klibanov OM
    Curr Opin Investig Drugs; 2009 Aug; 10(8):845-59. PubMed ID: 19649929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New kinds of AIDS drugs inhibit HIV entry into the cell. Entry inhibitors soon for oral administration].
    Fätkenheuer G
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():46-8. PubMed ID: 16385874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.
    Westby M; van der Ryst E
    Antivir Chem Chemother; 2010 Apr; 20(5):179-92. PubMed ID: 20413825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of heavily antiretroviral-experienced HIV-infected patients.
    Lunzen Jv
    AIDS Rev; 2007; 9(4):246-53. PubMed ID: 18219368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1.
    Taiwo B; Hicks C; Eron J
    J Antimicrob Chemother; 2010 Jun; 65(6):1100-7. PubMed ID: 20348088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
    Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
    Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of antiretroviral therapy: challenges and needs.
    Moreno S; López Aldeguer J; Arribas JR; Domingo P; Iribarren JA; Ribera E; Rivero A; Pulido F;
    J Antimicrob Chemother; 2010 May; 65(5):827-35. PubMed ID: 20228080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.
    Wilson LE; Gallant JE
    Clin Infect Dis; 2009 Jan; 48(2):214-21. PubMed ID: 19072245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection.
    Maeda K; Nakata H; Ogata H; Koh Y; Miyakawa T; Mitsuya H
    Curr Opin Pharmacol; 2004 Oct; 4(5):447-52. PubMed ID: 15351348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in HIV drug resistance.
    Cane PA
    J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antiretroviral therapies: strategic perspectives for the future].
    Reynes J
    Med Trop (Mars); 2007 Aug; 67(4):367. PubMed ID: 17926796
    [No Abstract]   [Full Text] [Related]  

  • 17. [New antiretroviral drugs. Improved pharmacokinetics and simpler dose schedules].
    Arastéh K; Müller M
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():14-7. PubMed ID: 11373768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
    Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral regimens for treatment-experienced patients with HIV-1 infection.
    Lagnese M; Daar ES
    Expert Opin Pharmacother; 2008 Apr; 9(5):687-700. PubMed ID: 18345948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.